Skip to main content
Figure 2. | BMC Infectious Diseases

Figure 2.

From: Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial

Figure 2.

The GMTs and Seroconversion rates of neutralizing antibodies against SARS-CoV-2 Prototype and Omicron BA.2 (PPS). For (A) GMTs of neutralizing antibodies in stratified age groups (3-5 years, 6-11 years and 12-17 years of age) and in all participants before booster vaccination (day 0) and after a booster dose of ZF2001 (day 14). (B) Seroconversion rates of neutralizing antibodies in different age subgroups (3-5 years, 6-11 years and 12-17 years of age) and in all participants after a booster dose of ZF2001 (day 14). GMTs, geometric mean titers. GMRs, geometric mean ratios (day 14 vs day 0). Seroconversion rate was defined as the percentage of participants with either a pre-vaccination neutralizing antibody titer <1:4 and a post-vaccination neutralizing antibody titer ≥1:4, or a pre-vaccination neutralizing antibody titer ≥1:4 and a ≥4 folds increase in post-vaccination neutralizing antibody titer. Numbers in parentheses are 95% confidence intervals (95% CIs). Error bars represent 95% CIs. Arrows represent GMRs.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us